author-photo

Xiling Jiang

Center for Drug Evaluation and Research

3

Papers

51

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy.

2021 Oncologist
Show All
- Source
- Cite
- Save
Citations (0)
FDA Approval Summary: Atezolizumab plus bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma.

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (33)
FDA Approval Summary: Alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer.

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (18)